Clinical data on how long pazopanib (Vita) tablets can help patients live

Pazopanib (Pazopanib) is an oral small molecule multi-target tyrosine kinase inhibitor that mainly targets vascular endothelial growth factor receptor (VEGFR) and platelet-derived growth factor receptor ( PDGFR) and stem cell factor receptor (c-Kit) and other signaling pathways, thereby inhibiting tumor angiogenesis and blocking tumor cell proliferation and metastasis. Pazopanib is mainly used for patients with advanced renal clear cell carcinoma (RCC) and certain soft tissue sarcomas. Its clinical effect has been verified in multiple randomized controlled trials, providing an important targeted therapy option for patients with advanced tumors.

In patients with advanced clear cell renal cell carcinoma, pazopanib showed certain advantages in overall survival (OS) and progression-free survival (PFS). VEG105192The study showed that the median progression-free survival of patients with advanced RCC who received pazopanib was approximately span>9.2 months, and the median overall survival time is approximately 22.9 months, which significantly extends the survival time of patients under standard supportive care. In addition, some patients can maintain disease stability for a long time, delay tumor progression, and improve their quality of life.

Pazopanib has also shown efficacy in patients with soft tissue sarcoma. Multicenter clinical studies have shown that for patients with advanced soft tissue sarcoma treated with pazopanib, the median progression-free survival can reach 4 to 6 months, and the overall survival is about 12 months. Although efficacy varies by tumor subtype and individual patient differences, pazopanib offers an important therapeutic opportunity for patients who are inoperable or have limited tolerance to chemotherapy.

It should be noted that the duration of efficacy of pazopanib is closely related to the individual patient's condition, tumor burden, and previous treatment experience. Patients should undergo regular imaging and laboratory monitoring during treatment to evaluate efficacy and adjust dosage. At the same time, due to possible side effects such as hypertension, abnormal liver function, and gastrointestinal discomfort, clinicians will take appropriate intervention measures based on patient tolerance. Overall, pazopanib can prolong progression-free survival and overall survival in patients with advanced renal clear cell carcinoma and soft tissue sarcoma, providing patients with considerable clinical benefits.

Reference link:https://www.drugs.com